BioNTech

BioNTech

Verified
Develops personalized immunotherapies with a focus on cancer medicine.

Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$3.7b (Public information from Jul 2024)
Company register number HRB 48720 (Mainz)
Mainz Rhineland-Palatinate (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2020202120222023202420252026
Revenues482m19.0b17.3b3.8b2.8b2.7b2.8b
% growth344 %3834 %(9 %)(78 %)(27 %)(2 %)2 %
EBITDA(42.1m)15.0b13.1b1.2b(639m)(756m)(883m)
% EBITDA margin(9 %)79 %76 %30 %(23 %)(28 %)(32 %)
Profit15.2m10.3b9.4b930m(552m)(504m)(636m)
% profit margin3 %54 %55 %24 %(20 %)(18 %)(23 %)
EV / revenue31.0x2.8x1.2x6.0x2.2x2.3x2.8x
EV / EBITDA-355.4x3.6x1.6x19.7x-9.4x-8.4x-8.8x
R&D budget645m<1m<1m1.8b---
R&D % of revenue134 %--47 %---

Source: Dealroom estimates

  • Edit

Recent News about BioNTech

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by BioNTech

Edit
Neon Therapeutics
ACQUISITION by BioNTech Jan 2020
MediGene
exited
InstaDeep
ACQUISITION by BioNTech Jan 2023
PhagoMed Biopharma
ACQUISITION by BioNTech Nov 2021
AexeRNA Therapeutics
ACQUISITION by BioNTech Nov 2023